|View printer-friendly version|
|CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration|
“We are thrilled with the continued progress in our alliance with
Investigational therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. By restricting activity to the tumor microenvironment, investigational Probody therapeutics directed against both validated and novel targets have been shown preclinically to enable anti-tumor efficacy with an enhanced safety window, relative to traditional antibody-based therapies.
About the Collaboration Agreement
Corporate Communications Contact: